Pfizer-Valneva Lyme disease vaccine shows 70% efficacy despite trial challenges

However, the trial faced unexpected challenges as lower-than-anticipated Lyme disease case numbers complicated the statistical analysis. The companies had originally projected higher infection rates among study participants, which would have strengthened the statistical power of their efficacy calculations.

Despite these methodological hurdles, both pharmaceutical companies expressed confidence in their data and announced plans to seek regulatory approval from health authorities. The vaccine targets multiple strains of Borrelia bacteria, the pathogen responsible for Lyme disease, which is transmitted through infected tick bites.

The last Lyme vaccine was withdrawn from the market in 2002 amid safety concerns and lawsuits, leaving prevention strategies limited to tick avoidance and prompt removal. Public health experts have long advocated for new vaccine development as tick-borne diseases continue spreading to previously unaffected regions.

Both companies plan to submit their application for regulatory review within the coming months, though approval timelines remain uncertain. If successful, the vaccine could become available to high-risk populations, including outdoor workers and residents of endemic areas, potentially reducing the burden of this debilitating disease.